Evidence map›Paper›PMID 41160264›Full record

ReviewMolecular biology reports2025

Heterologous immunity and antibody-dependent enhancement in respiratory virus infections.

Nur Hidayah Nor Isamuddin, Sazaly AbuBakar, Kim-Ling Chin, Nurhafiza Zainal

Abstract readReview
In one paragraph

Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Immune cell disorder in viral pneumonia.Journal of translational medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nur Hidayah Nor IsamuddinTropical Infectious Diseases Research and Education Centre (TIDREC), University of Malaya, Kuala Lumpur, 50603, Malaysia.
Sazaly AbuBakarTropical Infectious Diseases Research and Education Centre (TIDREC), University of Malaya, Kuala Lumpur, 50603, Malaysia.
Kim-Ling ChinInstitute for Advanced Studies, Advanced Studies Complex, Universiti Malaya, Kuala Lumpur, 50603, Malaysia. kimling@um.edu.my.
Nurhafiza ZainalDepartment of Medical Microbiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, 50603, Malaysia. nurhafizazainal@um.edu.my.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory viruses such as influenza viruses and coronaviruses pose persistent and evolving threats to global public health, driven by diverse mechanisms of immune evasion, cross-species transmission, and pandemic potential. Understanding the interplay between heterologous immunity and antibody-dependent enhancement (ADE) is crucial in delineating both protective and pathogenic immune responses following infection or vaccination. This review synthesizes current advances in the molecular and cellular mechanisms underlying virus-agnostic innate defenses, adaptive receptor diversification via V(D)J recombination, and the structural and functional bases of T and B cell cross-reactivity. The dualistic nature of antibody responses is examined in the context of Fc receptor- and complement-mediated ADE, emphasizing the implications for immune protection versus immunopathology. The impact of pre-existing cross-reactive immunity, primed by prior exposures to antigenically distinct viruses or vaccines, is discussed with evidence from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and other seasonal respiratory outbreaks. Finally, the review evaluates recent progress and ongoing challenges in universal vaccine development, proposing that the rational harnessing of broad-spectrum and cross-reactive immune mechanisms will be essential for enhancing pandemic preparedness and mitigating the risks associated with immune enhancement phenomena.

Indexed as

Antibody-Dependent EnhancementImmunity, HeterologousRespiratory Tract InfectionsAnimalsAntibodies, ViralCOVID-19Cross ReactionsHumansSARS-CoV-2Antibodies, ViralAntibody-dependent enhancementCross-reactivityHeterologous immunityRespiratory virusUniversal vaccine

Identifiers

PMID41160264
PMCPMC12572018

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.